IndusLaw, JSA, Quillon act on Kotak's ₹1,050 crore investment in Tirupati Medicare

The funds will enable Tirupati Medicare to work on their expansion efforts.
Tirupati Group
Tirupati Group
Published on
2 min read

Kotak Strategic Situations India Fund II and Kotak Alternate Asset Managers Limited have made a ₹1,050 crore investment in Tirupati Medicare Limited.

IndusLaw represented Tirupati Medicare on this investment deal.

The transaction team consisted of Shantanu Jindel (Partner), Shweta Gupta (Partner), Mandvi Singh (Senior Associate), Harshit Kumar (Senior Associate), Vatsal Agarwal (Associate) and Abhinav (Associate).

Shantanu Jindel, Shweta Gupta
Shantanu Jindel, Shweta Gupta

JSA advised TBO Korea Holdings Limited and Augusta Investments Zero Pte. Ltd. (collectively, "Affirma Capital") in the sale of its minority stake in Tirupati Medicare to Kotak.

The transaction team consisted of Sidharrth Shankar (Lead Partner), Prakriti Jaiswal (Partner), Aditya Vardhan Dayal (Principal Associate) and Pranav Rao N (Associate).

Sidharrth Shankar, Prakriti Jaiswal
Sidharrth Shankar, Prakriti Jaiswal

Quillon Partners also advised on this transaction.

Tirupati Group
Tirupati Group

This investment will support Tirupati's expansion plans and is likely to facilitate a complete exit for Affirma Capital, which had been a significant minority shareholder since its ₹350 crore investment in 2019.

Founded in 2005, Tirupati Medicare is one of the largest and fastest growing company with pioneers in providing end-to-end solutions from research to product launch, with multiple state-of-the-art manufacturing facilities. The group is highly diversified, catering to a variety of broad segments like Pharmaceuticals, Nutraceuticals, Ayurveda, Veterinary, Probiotics and a niche segment like Sports Nutrition.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Bar and Bench - Indian Legal news
www-barandbench-com.demo.remotlog.com